Thomas K Karikari, PhD
Education & Training
Selected Honors & Awards
- Karikari TK*, Pascoal TA*, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J, Schll M, Massarweh G, Soucy J-P, Hglund K, Brinkmalm G, Mattsson N, Palmqvist S, Gauthier S, Stomrud E, Zetterberg H, Hansson O, Rosa-Neto P & Blennow K (2020). Blood phosphorylated tau 181 as a biomarker for Alzheimers disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology 19, 422433. https://doi.org/10.1016/S1474-4422(20)30071-5 *Joint first authors
- Karikari TK*, Emersic A*, Vrillon A*, Rodriguez JL, Ashton NJ, Kramberg MG, Dumurgier J, Hourregue C, Cucnik S, Brinkmalm G, Rot U, Zetterberg H, Paquet C & Blennow K (2020). Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimers disease diagnosis Alzheimers and Dementia, (2021) May;17(5):755-767. doi: 10.1002/alz.12236. Epub 2020 Nov 30. *Joint first authors
- Karikari TK*, Benedet AL*, Ashton NJ*, Lantero Rodriguez J, Snellman A, Surez-Calvet M, Saha-Chaudhuri P, Lussier F, Kvartsberg H, Rial AM, Pascoal TA, Andreasson U, Schll M, Weiner MW, Rosa-Neto P, Trojanowski JQ, Shaw LM, Blennow K & Zetterberg H (2020). Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimers Disease Neuroimaging Initiative. Molecular Psychiatry. https://doi.org/10.1038/s41380-020-00923-z *Joint first authors
Genetic Risk for Attention-Deficit/Hyperactivity Disorder Predicts Cognitive Decline and Development Of Alzheimer’s Disease Pathophysiology in Cognitively Unimpaired Older Adults
Attention-deficit/hyperactivity disorder (ADHD) persists in older age and may be a risk factor for cognitive impairment and Alzheimer’s disease. A recent study published in Molecular Psychiatry aimed to determine whether genetic liability for ADHD, as measured by a well-validated ADHD polygenic risk score, is associated with cognitive decline and the development of Alzheimer’s disease pathophysiology in cognitively...
Now in the Journal Brain: Brain-derived Tau Is a Novel Biomarker for Alzheimer’s Disease-type Neurodegeneration
A group of Alzheimer’s and dementia investigators have published a study in Brain reporting the development and the analytical and clinical validation of a novel biomarker for Alzheimer’s disease. Led by Thomas Karikari, PhD (Assistant Professor of Psychiatry)—and including senior scientists Henrik Zetterberg, MD, PhD, and Kaj Blennow, MD, PhD, internationally renowned leaders in blood biomarker discovery at...
The Department of Psychiatry Welcomes Three New Research Faculty Members
Pitt Psychiatry extends a warm welcome to three new research faculty members: Candice Biernesser, PhD, LCSW (Assistant Professor of Psychiatry) Dr. Biernesser earned her PhD from the Department of Behavioral and Community Health Sciences at the University of Pittsburgh School of Public Health, then joined the Pitt Department of Psychiatry as a postdoctoral fellow in the Department’s National Institute of Mental...
Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease
In Alzheimer’s disease, reactive astrocytes can play an important role in the pathophysiology of the disease. Amyloid-β and tau tangles—the two main pathological hallmarks of Alzheimer’s disease—are associated with astrocyte reactivity. However, knowledge about amyloid-β- and tau-specific contributions to reactive astrocyte biomarkers in patients with Alzheimer’s disease is limited. To improve our understanding of...